MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Up 0.3% – Should You Buy?

Shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) traded up 0.3% during trading on Tuesday . The stock traded as high as $0.97 and last traded at $0.9540. 20,712 shares changed hands during trading, a decline of 85% from the average session volume of 134,455 shares. The stock had previously closed at $0.9515.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Friday, March 27th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold”.

MIRA Pharmaceuticals Stock Up 0.3%

The firm has a market cap of $40.09 million, a P/E ratio of -0.73 and a beta of 1.43. The stock’s 50-day moving average is $1.01 and its 200-day moving average is $1.20.

MIRA Pharmaceuticals (NASDAQ:MIRA) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.03) earnings per share for the quarter.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in MIRA Pharmaceuticals by 100.0% during the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock worth $412,000 after buying an additional 136,438 shares in the last quarter. Fifth Third Bancorp acquired a new position in MIRA Pharmaceuticals in the 4th quarter valued at approximately $30,000. First American Bank raised its holdings in MIRA Pharmaceuticals by 20.0% in the 4th quarter. First American Bank now owns 60,000 shares of the company’s stock valued at $91,000 after acquiring an additional 10,000 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of MIRA Pharmaceuticals by 129.8% in the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after acquiring an additional 25,816 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of MIRA Pharmaceuticals in the 2nd quarter worth approximately $26,000. Institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.